Novel radiopeptide shows high efficacy without high toxicity
Tuesday 2 August 2011
A new radiopeptide called 213Bi-DOTATOC appears to show high efficacy in treating neuroendocrine tumours without high toxicity. Appropriate dosing is a key focus of research into alpha therapy, because of its high cytotoxicity; the new radiopeptide offers hope that more powerful, effective doses can be used.
>> http://www.medscape.com/viewarticle/744483?sssdmh=dm1.695428&src=nldne
European Oncology Nursing SocietyAvenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu